Last Updated: November 8, 2026

ORVATEN Drug Patent Profile

Name: ORVATEN Drug Patent, Exclusivity, and Generic Launch Dataset
Creator: DrugPatentWatch
License: https://www.drugpatentwatch.com/terms.php

« Back to Dashboard

When do Orvaten patents expire, and when can generic versions of Orvaten launch?

Orvaten is a drug marketed by Beijing Yiling and is included in one NDA.

The generic ingredient in ORVATEN is midodrine hydrochloride. There is one drug master file entry for this compound. Thirty-three suppliers are listed for this compound. Additional details are available on the midodrine hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Orvaten

A generic version of ORVATEN was approved as midodrine hydrochloride by MYLAN PHARMS INC on September 10^th, 2003.

Start Trial

AI Deep Research

Questions you can ask:

What is the 5 year forecast for ORVATEN?
What are the global sales for ORVATEN?
What is Average Wholesale Price for ORVATEN?

Summary for ORVATEN

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	3
Raw Ingredient (Bulk) Api Vendors:	89
Clinical Trials:	1
Patent Applications:	322
DailyMed Link:	ORVATEN at DailyMed

Drug patent expirations by year for ORVATEN

Recent Clinical Trials for ORVATEN

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
The Craig H. Neilsen Foundation	Phase 4
James J. Peters Veterans Affairs Medical Center	Phase 4

See all ORVATEN clinical trials

Pharmacology for ORVATEN

Drug Class	alpha-Adrenergic Agonist
Mechanism of Action	Adrenergic alpha-Agonists

US Patents and Regulatory Information for ORVATEN

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Beijing Yiling	ORVATEN	midodrine hydrochloride	TABLET;ORAL	076725-001	Nov 3, 2004	AB	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Beijing Yiling	ORVATEN	midodrine hydrochloride	TABLET;ORAL	076725-002	Nov 3, 2004	AB	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Beijing Yiling	ORVATEN	midodrine hydrochloride	TABLET;ORAL	076725-003	Nov 3, 2004	AB	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.